Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease

Source: Pharmacy Times articles

The fixed-dose combination yielded a 49% greater reduction in low density lipoprotein cholesterol (LDL-C) compared with placebo.
Read More